Health

Malaria vaccines are now part of routine immunisation in a growing number of African countries.

The vaccine has already cut child malaria deaths by a specific large percentage across the continent.

Coverage is reaching most eligible children in rollout districts.

In clinical trials, the malaria vaccines showed real impact.

The WHO ended the mpox global health emergency on 5 September 2025.

Africa CDC kept its own continental emergency in place for months after the WHO lifted its, and ended it in January 2026.

Ending the emergency declarations means mpox is finished in Africa.

In July 2025 the WHO recommended twice-yearly injectable lenacapavir for HIV prevention.

In its main trial, the injection prevented every recorded HIV infection among more than 2,000 participants.

Lenacapavir will be available at about $40 per person per year in African countries from 2027.

BioNTech inaugurated its site in Kigali, Rwanda, on 18 December 2023, on the occasion of the set-up of its first BioNTainer manufacturing unit.

BioNTech committed a total investment of approximately USD 150 million for the site, which covers approximately 35,000 square metres and will have approximately 100 employees once fully operational.